What do you recommend for patients with stage 3 MSI-H colorectal cancer who are ineligible for oxaliplatin-based adjuvant therapy?
Answer from: Medical Oncologist at Community Practice
I typically don’t offer adjuvant therapy to those patients. 5-Fu/Xeloda does not benefit as a single agent in this patient population. If Oxaliplatin-based treatments cannot be given, then there are practically no other options that are associated with a survival benefit.
Answer from: Medical Oncologist at Community Practice
Similar questions on this topic have come up more than once on theMednet. Unfortunately, we still do not have any results from the two phase III randomized trials to guide immunotherapy in this setting. While we have data showing quite impressive results with immune checkpoint inhibitors in MSI-H/dM...